iTeos Therapeutics, Inc. - Common stock, par value $0.001 per share (ITOS)

Historical Holders from Q3 2020 to Q3 2025

Symbol
ITOS
CUSIP
46565G104
Type / Class
Equity / Common stock, par value $0.001 per share
Shares outstanding
10K
All holders as of September 30, 2025
Q3 2025
Total 13F shares, excl. options
217
Holdings value
$2.51K
% of all portfolios
0%
Grand Portfolio weight change
-0.001%
Number of holders
1
Number of sells
-131
Average Value change %
0%
Average sells %
-0.004%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of iTeos Therapeutics, Inc. - Common stock, par value $0.001 per share (ITOS)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
EcoR1 Capital, LLC 27.9% +86.7% $78.6M $36.4M 10.7M +86.5% EcoR1 Capital, LLC May 15, 2025
BlackRock Portfolio Management LLC 6.1% $17.1M 2.33M BlackRock Portfolio Management LLC Mar 31, 2025
BlackRock, Inc. 5.7% $16M 2.18M BlackRock, Inc. Mar 31, 2025
RA CAPITAL MANAGEMENT, L.P. 4.9% -50% $15.7M -$14.9M 2.13M -48.7% RA Capital Management, L.P. May 15, 2025
MPM BioVentures 2014, L.P. 4.7% $13.3M 1.8M ANSBERT GADICKE May 13, 2025
TANG CAPITAL MANAGEMENT LLC 100% +900% $101K -$38.6M 10K -99.7% TANG CAPITAL MANAGEMENT, LLC Aug 29, 2025

Institutional Holders of iTeos Therapeutics, Inc. - Common stock, par value $0.001 per share (ITOS)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 217 $2.51K -$376M $11.56 1
2025 Q2 37.8M $377M +$70.8M $9.97 134
2025 Q1 37M $221M +$13M $5.97 128
2024 Q4 34.1M $262M -$45.4M $7.68 133
2024 Q3 36.6M $373M -$1.63M $10.21 146
2024 Q2 36.2M $537M +$26.1M $14.84 132
2024 Q1 34.5M $471M -$29K $13.64 127
2023 Q4 35M $383M -$6.01M $10.95 130
2023 Q3 35.5M $389M +$7.23M $10.95 141
2023 Q2 34.5M $457M -$20.4M $13.24 140
2023 Q1 36M $489M -$5.82M $13.61 149
2022 Q4 36.2M $707M -$15.8M $19.53 144
2022 Q3 36.6M $698M -$16.3M $19.05 133
2022 Q2 37.3M $768M +$2.33M $20.60 149
2022 Q1 36M $1.16B +$80.8M $32.18 154
2021 Q4 33.4M $1.55B +$105M $46.56 115
2021 Q3 31.2M $841M +$47.3M $27.00 76
2021 Q2 29.5M $756M -$27.4M $25.65 82
2021 Q1 30.1M $1.03B +$89.1M $34.18 78
2020 Q4 29.3M $987M +$60.5M $33.82 72
2020 Q3 25M $614M +$614M $24.67 54